⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Nirsevimab

نیرسویماب

⚠ Unverified

🦠 Antiinfectives For Systemic UseAnti-RSV monoclonal antibody

🤰 Pregnancy:No data 🤱 Breastfeeding:No data 👶 Children:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA761328 ATC J06BD08

Market / country: 🇺🇸 USA

Beyfortus (US)

🧮 Dose calculator

Disease / regimen

RSV prophylaxis in infants · Regimen source: FDA Beyfortus · 2.1, Table 1

• Born during the RSV season: from birth. Born outside the season: once before the season starts. Second season for high-risk children up to 24 months: 200 mg regardless of weight. Can be given with childhood vaccines (separate syringe and site). FDA Beyfortus · 2.1, Table 1 FDA Beyfortus · 2.2

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ History of serious hypersensitivity (including anaphylaxis) to nirsevimab. FDA Beyfortus · 4

Formulations

50 mg/0.5 mL prefilled syringe — injection 🇺🇸 USA FDA Beyfortus · 3
100 mg/mL prefilled syringe — injection 🇺🇸 USA FDA Beyfortus · 3

👥 Special populations

🤰 PregnancyNo data
Label: an infant product; not indicated for adult women. FDA Beyfortus · 8.1
“BEYFORTUS is not indicated for use in females of reproductive potential.”
🤱 BreastfeedingNo data
Label: an infant product; not indicated for adult women. FDA Beyfortus · 8.2
“BEYFORTUS is not indicated for use in females of reproductive potential.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Beyfortus · 8.4
“The safety and effectiveness of BEYFORTUS have been established for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.”
👴 Older adultsNo data
The source for this drug has no section for this group.
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA761328
DailyMed (FDA label)FDA Beyfortus
MedlinePlus (NIH)Nirsevimab-alip
WHO ATC/DDDJ06BD08
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Beyfortus · 3 FDA Beyfortus · 2.1, Table 1 FDA Beyfortus · 2.2 FDA Beyfortus · 4 FDA Beyfortus · 8.1 FDA Beyfortus · 8.2 FDA Beyfortus · 8.4 FDA Beyfortus · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified